OMEGA-3 POLYUNSATURATED FAT T Y ACIDS, STATINS AND THEIR COMBINATION IN THE TRE ATMENT OF PATIENTS WITH T YPE 2 DIABETES MELLITUS WITH CARDIOVASCULAR AUTONOMIC NEUROPATHY
DOI:
https://doi.org/10.21856/j-PEP.2017.4.04Keywords:
type 2 diabetes mellitus, cardiovascular autonomic neuropathy, insulin resistance, lipids, endothelin-1, prostacyclin I2-thromboxane A2 system, heart rate variability, ω-3 polyunsaturated fatty acids, statins, combined therapy.Abstract
75 patients with type 2 diabetes mellitus and functional stage of cardiovascular autonomic neuropathy were divided into 4 groups: patients of 1st group (n = 21) received one capsule/day of the ω-3 polyunsaturated fatty acids (ω-3 PUFAs) in addition to standard treatment; patients of 2nd group (n = 22) — simvastatin 20 mg/daily; patients of 3rd group (n = 17) — one capsule of the ω-3 PUFAs and simvastatin 10 mg/daily; patients of 4rd group (n = 22) — control group. The duration of the study was 3 months. Administration of ω-3 PUFAs promoted to the statistically significant decrease in triglycerides, atherogenic coefficient (AC) and increase of high-density lipoprotein cholesterol (HDL-C). Prescription of simvastatin was accompanied by statistically significant decrease of circulating insulin (IRI), insulin resistance (HOMA-IR), total cholesterol, low-density lipoprotein cholesterol, AC, thromboxane B2 (ТХВ2 ), TXB2/6-ketoprostoglandine F1α (6-ketoPGF1α) and increase of HDL-C, endothelin-1 (ЕТ-1), 6-ketoPGF1α levels; time-domain and spectral parameters of heart rate variability (HRV). Combined administration of ω-3 PUFAs and simvastatin promoted to the most statistically significant changes of IRI, HOMA-IR, lipid profile, ET-1, ТХВ2, TXB2/6-ketoPGF1α levels; time-domain and spectral parameters of HRV.
References
Spallone V, Ziegler D, Freeman R, et al. Diabetes Metab Res Rev 2011; 27: 639-653.
Sytze Van Dam P, Cotter MA, Bravenboer B, et al. Eur J Pharmacol 2013; 5: 1-3.
Valensi P. Cardiovascular autonomic neuropathy. Diabetes in cardiovascular disease: A companion to braunworld’s heart disease, Eds. DK. McGuire, N Marx, Amsterdam, 2015: 361-368.
Serhiyenko VA, Serhiyenko AA, Efimov AS. J NAMS Ukraine 2011;17: 353-367.
DePace Nl, Mears JP, Yayac M, et al. Heart Int 2014;9: 37-44.
Serhiyenko VA, Serhiyenko AA. World J Diabetes 2015;6: 245-258.
Garcнa-Sacristбn A, Hernбndez M, Prieto D, et al. Br J Pharmacol 2014;171: 5682-5695.
Nikishin AG, Nurbaev TA, Khasanov MS, et al. I J B M 2014;4: 138-142.
Ascaso JF. Endocrinol Nutr 2010;57: 210-219.
Goit RK, Paudel BH, Khadka R, et al. J Diabetes Investig 2014;56: 722-727.
Endo J. J Cardiol 2016;67: 22-27.
Ewing D. Br Med J 1982;285: 916-918.
Lapach SN, Chubenko AV, Babich PN. Statisticheskie metody v mediko-biologicheskih issledovanijah s ispol’-zovaniem Exel, Кyev, 2000: 320 p.
American Diabetes Association. Diabetes Care 2017;40: 1-132.
Serhiyenko VA. J NAMS Ukraine 2012;18: 205-216.
Serhiyenko VA, Serhiyenko LM, Serhiyenko AA. New York: Nova Science Publishers 2017;3: 79-154.
ISSN 
ISSN 
